Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sigvotatug vedotin
- Development stage
- Phase 3
- Lead developer
- Pfizer
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Sigvotatug vedotin is an investigational antibody-drug conjugate (ADC) targeting integrin beta-6 (IB6), a cell surface receptor implicated in tumor pathogenesis and invasiveness. The drug consists of three main components: a humanized IgG1 monoclonal antibody directed against IB6, the cytotoxic payload monomethyl auristatin E (MMAE), and a protease-cleavable maleimidocaproyl-valine-citrulline (mc-vc) linker that attaches MMAE to the antibody. Upon binding to IB6-expressing tumor cells, the ADC is internalized and MMAE is released intracellularly, disrupting microtubule polymerization and inducing apoptosis. Sigvotatug vedotin is being developed primarily for non-small cell lung cancer (NSCLC) but is also under investigation for other solid tumors including head and neck squamous cell carcinoma, esophageal cancer, cutaneous squamous cell carcinoma, ovarian cancer, pancreatic adenocarcinoma, bladder cancer, cervical cancer, gastric cancer, HER2-negative breast cancer, gastroesophageal junction adenocarcinoma[1][4][5][6].
- Other names
- SVhumanised IgG1 monoclonal antibody against integrin beta-6 conjugated to monomethyl auristatin E via a valine-citrulline linker
02
Targets
ITGB6 (Integrin beta-4)
Beyond the preview
Go deeper on sigvotatug vedotin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sigvotatug vedotin.